Prescription for Fairness: A New Approach to Tort Liability of Brand-Name and Generic Drug Manufacturers

Citation data:

60 Duke Law Journal 1123 (2011), Vol: 60, Issue: 5, Page: 1123-1191

Publication Year:
2011
Usage 1395
Downloads 1312
Abstract Views 83
Repository URL:
https://scholarship.law.duke.edu/dlj/vol60/iss5/2
Author(s):
Rostron, Allen
Publisher(s):
Duke University School of Law
Tags:
Pharmaceutical industry; Patient package inserts; Products liability; Brand name products; Generic drugs
article description
Over the past two decades, courts have consistently ruled that the manufacturer of a brand-name prescription drug cannot be liable for injuries suffered by those taking generic imitations of its product. This meant that a patient injured by a generic drug could have no remedy at all because in many instances the generic drug manufacturer would escape liability on the ground that it did not produce any information on which the patient's doctor relied. It was a perplexing dilemma. The generic drug manufacturer made the product that the plaintiff received, the brand-name manufacturer produced all of the information the patient's doctor saw, and neither manufacturer could be held liable even if each acted negligently. The California Court of Appeal recently issued a stunning decision in which it concluded that a brand-name drug manufacturer could be liable to a plaintiff who took a generic version of its product. The reaction to the decision has been overwhelmingly negative. Commentators have condemned the decision as one of the worst rulings made by any court in recent years. Judges around the country have dismissed it as a misguided aberration from the otherwise strong judicial consensus on the issue. Although the decision has been the subject of scathing criticism, this Article argues that the California court's ruling actually represents the first time that a court has properly examined this issue. In addition, the Article points out some weaknesses in the California court's reasoning and proposes a novel general framework for analyzing the liability of brand-name and generic drug manufacturers.